ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03191383
Recruitment Status : Withdrawn (Study was canceled due to instability of the PreF antigen during manufacturing. No safety concern has been identified in past or ongoing studies.)
First Posted : June 19, 2017
Last Update Posted : October 15, 2018
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the investigational GSK RSV vaccine in pregnant women aged 18 to 40 years and infants born to the vaccinated women

Condition or disease Intervention/treatment Phase
Respiratory Syncytial Virus Infections Biological: RSV vaccine (GSK3003891A) formulation 1 Biological: RSV vaccine (GSK3003891A) formulation 2 Biological: RSV vaccine (GSK3003891A) formulation 3 Drug: Placebo (Formulation buffer S9b) Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
Actual Study Start Date : July 11, 2017
Actual Primary Completion Date : July 14, 2017
Actual Study Completion Date : July 14, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: GSK3003891A vaccine formulation 1 mother Group
Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
Biological: RSV vaccine (GSK3003891A) formulation 1
Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

Experimental: GSK3003891A vaccine formulation 2 mother Group
Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
Biological: RSV vaccine (GSK3003891A) formulation 2
Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

Experimental: GSK3003891A vaccine formulation 3 mother Group
Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
Biological: RSV vaccine (GSK3003891A) formulation 3
Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

Placebo Comparator: Control group
Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.
Drug: Placebo (Formulation buffer S9b)
Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

No Intervention: GSK3003891A vaccine formulation 1 infant Group
Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine
No Intervention: GSK3003891A vaccine formulation 2 infant Group
Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine
No Intervention: GSK3003891A vaccine formulation 3 infant Group
Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine
No Intervention: Control infant Group
Infants born to mothers who received a single placebo injection



Primary Outcome Measures :
  1. Number of subjects with solicited local adverse events (AEs) [ Time Frame: During a 7-day follow-up period after vaccination (i.e. the day of vaccination and 6 subsequent days) ]
    Assessed solicited local symptoms are pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevents normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

  2. Number of subjects with solicited general AEs [ Time Frame: During the 7-day follow-up period after vaccination (i.e. the day of vaccination and 6 subsequent days) ]
    Assessed solicited general symptoms are fatigue, fever [defined as oral/axillary/tympanic route temperature equal to or above 37.5 degrees Celsius (°C) or ≥ 38 °C for rectal route], gastrointestinal symptoms [nausea, vomiting, diarrhoea and/or abdominal pain] and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevents normal activity. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination

  3. Number of subjects with unsolicited AEs [ Time Frame: During a 30-day follow-up period after vaccination (i.e. the day of vaccination and 29 subsequent days) ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevents normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

  4. Number of subjects with haematological abnormalities [ Time Frame: At Day 0 ]
    Haematological laboratory abnormalities include haemoglobin level, white blood cell count [WBC], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.

  5. Number of subjects with haematological abnormalities [ Time Frame: At Day 7 ]
    Haematological laboratory abnormalities include haemoglobin level, white blood cell count [WBC], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.

  6. Number of subjects with biochemical abnormalities [ Time Frame: At Day 0 ]
    Biochemical laboratory abnormalities include alanine amino-transferase [ALT], aspartate amino-transferase [AST], creatinine and blood urea nitrogen.

  7. Number of subjects with biochemical abnormalities [ Time Frame: At Day 7 ]
    Biochemical laboratory abnormalities include alanine amino-transferase [ALT], aspartate amino-transferase [AST], creatinine and blood urea nitrogen.

  8. Number of subjects with any serious adverse events (SAEs) [ Time Frame: From study start (Day 0) up to 6 months after delivery ]
    SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

  9. Number of infant subjects with any SAEs [ Time Frame: From birth up to 6 months after birth ]
    SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

  10. Number of subjects with pregnancy outcomes [ Time Frame: From study start (Day 0) up to delivery ]
    Pregnancy outcomes include live birth with no congenital anomalies, live birth with congenital anomalies, foetal death/still birth with no congenital anomalies, foetal death/still birth with congenital anomalies, elective/therapeutic termination with no congenital anomalies and elective/therapeutic termination with congenital anomalies.

  11. Number of subjects with pregnancy-related AEs of specific interest [ Time Frame: From study start (Day 0) up to delivery ]
    Pregnancy-related adverse events of specific interest include: gestational diabetes, gestational liver disease (including obstetric cholestasis and acute fatty liver of pregnancy), chorioamnionitis, labour protraction and arrest disorders, maternal sepsis, pregnancy-related hypertension, preterm premature rupture of membranes, premature labour, intrauterine growth restriction/poor foetal growth, pre-eclampsia and eclampsia, vaginal or intrauterine haemorrhage, medical conditions necessitating early delivery (induced labour or urgent C-section) (placenta abruption, uterine infection, oligohydramnios, etc), maternal death.

  12. Number of infant subjects with AEs of specific interest [ Time Frame: From birth up to 6 months after birth ]
    Infant-related AEs of specific interest include preterm birth, neonatal death, low birth weight and/or small for gestational age, neonatal sepsis, foetal/perinatal distress or asphyxia, failure to thrive/growth deficiency, congenital anomalies and neurodevelopmental delay.


Secondary Outcome Measures :
  1. Number of infant subjects with SAEs [ Time Frame: From birth and up to study end (Year 2) ]
    SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

  2. Number of infant subjects with AEs potentially related to maternal vaccination [ Time Frame: From birth up to study end (Year 2) ]
    Related infant AEs = AEs occurring in the infant assessed by the investigator as potentially related to the vaccination of the mother.

  3. Number of infant subjects with neuro-developmental delays [ Time Frame: At Year 1 and Year 2 ]

    Infant subjects with Ages and Stages Questionnaires version 3 (ASQ-3) scores in the grey and black zones for any of the 5 developmental areas or domains (communication, gross motor skills, fine motor skills, problem solving and personal-social) :

    Grey zone (i.e. Monitoring zone) score means that the child's score falls ≥ 1 but <2 standard deviations below the mean score in any developmental area.

    Black zone (i.e. Referral zone) score means that the child's score falls below the cut-off (i.e. 2 standard deviations below the mean score) in any developmental area. Infant subjects scoring in the black zone in any of the 5 domains of the ASQ-3 will be referred for formal neurological evaluation


  4. Number of infant subjects referred for formal neurological evaluation [ Time Frame: At Year 1 and Year 2 ]
    Neuro-developmental formal evaluation will be performed, for infants with ASQ3 black zone scores, using the Bayley Scale for Infant Development, Version III (BSID-III) or an equivalent.

  5. Number of infant subjects with confirmed developmental delay [ Time Frame: At Year 1 and Year 2 ]
    Infants confirmed as having neuro-developmental delay following formal evaluation using the Bayley Scale for Infant Development, Version III (BSID-III) or an equivalent.

  6. Neutralizing antibody titres against RSV-A, for all vaccinated mothers [ Time Frame: At pre-vaccination (Day 0), Day 30 and Day 60 post vaccination and at delivery ]
    Titres will be expressed as geometric mean titres (GMTs)

  7. Neutralizing antibody titres against RSV-B, for all vaccinated mothers [ Time Frame: At pre-vaccination (Day 0), Day 30 and Day 60 post vaccination and at delivery ]
    Titres will be expressed as geometric mean titres (GMTs)

  8. Palivizumab competing antibody (PCA) concentrations, for all vaccinated mothers. [ Time Frame: At pre-vaccination (Day 0), Day 30 and Day 60 post-vaccination and at delivery ]
    Concentrations will be expressed as geometric mean concentrations (GMCs)

  9. Neutralizing antibody titres against RSV-A, for all infants born to vaccinated mothers [ Time Frame: At birth, at Month 3 and at Month 6 ]
    Titres will be expressed as geometric mean titres (GMTs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.

  10. Neutralizing antibody titres against RSV-B, for all infants born to vaccinated mothers [ Time Frame: At birth, at Month 3 and at Month 6 ]
    Titres will be expressed as geometric mean titres (GMTs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.

  11. PCA concentrations, for all infants born to vaccinated mothers [ Time Frame: At birth, at Month 3 and at Month 6 ]
    Concentrations will be expressed as geometric mean concentrations (GMCs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.

  12. Number of infant subjects with lower respiratory tract infection (LRTI), severe LRTI and respiratory tract infection (RTI) with parental concern (according to the case definitions) associated with a respiratory syncytial virus (RSV) infection [ Time Frame: From birth up to study end (Year 2) ]
    Occurrence of RSV-LRTI, severe RSV-LRTI, RSV-RTI with parental concern

  13. Number of subjects (vaccinated mothers) with medically-attended (MA) RTI associated with an RSV infection [ Time Frame: From Day 0 up to Month 6 post delivery ]
    Occurrence of RSV associated MA-RTI. A MA-RTI is defined as a visit of the mother to a health care professional for any respiratory symptom, including cough, sputum production and difficulty breathing



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written informed consent for study participation of the mother obtained from the mother or the mother and father, as applicable by local law, prior to performance of any study specific procedure.
  • Written informed consent for study participation of the infant obtained from the infant's mother and/or father, as applicable by local law, or legally acceptable representative [LAR] prior to performance of any study specific procedure.
  • Subjects between, and including, 18 and 40 years of age at the time of the first study visit.
  • Pregnant females > 24 weeks of gestation at the time of screening and at 28 0/7 to 33 6/7 weeks of gestation at the time of vaccination, as established by ultrasound examination and last menstrual period date.
  • Healthy pregnant females as established by medical history and clinical examination before entering into the study.
  • Pregnant females not at high risk for complications, as determined by the obstetrical risk assessment form.
  • No significant foetal findings observed during a second or third trimester ultrasound.
  • Subjects who are willing to provide cord blood.
  • Subjects who do not plan to give their child for adoption or place the child in care.

Inclusion Criteria infants:

• Re-signed written informed consent for study participation of the infant obtained from the infant's mother and/or father, as applicable by local law, or LAR.

Exclusion Criteria:

  • Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before vaccination , or planned use during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before vaccination and ending at delivery with the exception of seasonal influenza vaccine and diphtheria, tetanus, pertussis/tetanus, diphtheria, pertussis [dTpa/Tdap] vaccine as part of standard of care which may be administered ≥ 15 days before or after study vaccination.
  • Chronic administration of systemic immunosuppressants or other immune-modifying drugs, as well as administration of long-acting immune-modifying drugs during the period starting 6 months prior to study vaccination, or planned administration up to delivery. Topical steroids are allowed. Inhaled steroids are allowed up to the limit of ≤500 µg/day for beclomethasone or fluticasone, or ≤ 800 µg/day for budesonide.
  • Administration of immunoglobulins (with the exception of prophylactic anti-Rh0D immune globulin) and/or any blood products during the period starting 3 months before study vaccination or planned administration during the study period.
  • Previous experimental vaccination against RSV.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Low lying placenta during the current pregnancy, unless there is documented sonographic evidence that the placenta has moved up prior to enrolment.
  • Any abnormal finding observed in nuchal translucency scan, serum testing and any other prenatal tests, if conducted.
  • Incompetent cervix or cerclage during the current pregnancy.
  • Having received medical treatment for suspected preterm delivery during the current pregnancy.
  • Prior preterm delivery or having ongoing intervention in current pregnancy to prevent preterm delivery.
  • Prior stillbirth or neonatal death, or ≥ 2 spontaneous abortions.
  • Personal history of major congenital anomalies or early onset of eclampsia/pre-eclampsia in previous pregnancy.
  • 1st degree relatives family history of major congenital anomalies and/ or hereditary immunodeficiency.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • Hemodynamically significant cardiac disorders.
  • Gestational diabetes as determined by glucose challenge/tolerance test conducted after 20 weeks of gestation or as per local recommendations of the country, requiring intervention other than diet for control. In countries where glucose challenge/tolerance testing is not routinely performed in all pregnant women, should the screening urinalysis test show presence of glucose in urine, a glucose challenge/tolerance test should be performed and results should be available prior to enrolment, in order to exclude gestational diabetes prior to subject receiving the study vaccine.
  • History of gestational diabetes in previous pregnancy(ies).
  • Hypertension during the current pregnancy as defined below or if any antihypertensive medication is being provided, or history of hypertension requiring antihypertensive medication:

Hypertension during current pregnancy is defined as:

  • a blood pressure systolic > 140 and/or diastolic 90 mmHg, documented in at least 2 separate measurements .

    • Current obstetric cholestasis or history of obstetric cholestasis.
    • Asthma and/or chronic obstructive pulmonary disease [COPD] if the subject is receiving treatment with chronic systemic glucocorticoids at any dose or inhaled glucocorticoids > 500 µg/day of beclomethasone or fluticasone, or > 800 µg/day of budesonide.
    • Significant neuro-psychiatric illness deemed likely to interfere with protocol compliance, safety reporting or receipt of pre-natal care, or requiring treatment with psychotropic drugs.
    • Diagnosed with Zika virus infection or suspected to have or have had Zika virus infection during the current pregnancy.
    • Known HIV infection, as assessed by local standard of care serologic tests conducted during the current pregnancy and prior to enrolment.
    • Known or suspected Hepatitis B virus [HBV] or Hepatitis C virus [HCV] infection.
    • Known infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Rubella, cytomegalovirus [CMV] or primary Herpes Simplex.
    • Known foetal anomalies in the current pregnancy.
    • Any clinically significant haematological and/or biochemical laboratory abnormality.
  • Subjects with haematological/ biochemical values out of normal range which are expected to be temporary may be re-screened at a later date within the allowed time interval.

    • Acute disease and/or fever within 3 days prior to enrolment .

  • Fever is defined as temperature ≥ 37.5°C/99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C/100.4°F for rectal route.
  • Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
  • For subjects with acute disease and/ or fever at the time of enrolment, Visit 1 may be scheduled at a later date within the allowed time interval and gestational age.

    • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
    • Hypersensitivity to latex.
    • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
    • History of drug or alcohol abuse within the past 2 years.
    • Any condition which, in the investigator's opinion, would increase the risks of study participation to the unborn infant.
    • Planned move to a location that will prohibit participating in the trial until study end.

Exclusion Criteria infants:

• Any condition which, in the investigator's opinion, would increase the risks of study participation to the infant.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03191383


Locations
United States, Kansas
GSK Investigational Site
Newton, Kansas, United States, 67114
United States, New York
GSK Investigational Site
Syracuse, New York, United States, 13210
United States, Washington
GSK Investigational Site
Ellensburg, Washington, United States, 98926
Finland
GSK Investigational Site
Oulu, Finland, 90220
GSK Investigational Site
Seinajoki, Finland, 60100
Spain
GSK Investigational Site
Aravaca, Spain, 28023
GSK Investigational Site
Burgos, Spain, 09006
GSK Investigational Site
Madrid, Spain, 28040
GSK Investigational Site
Majadahonda (Madrid), Spain, 28222
GSK Investigational Site
Santiago de Compostela, Spain, 15706
GSK Investigational Site
Santiago, Spain, 15705
GSK Investigational Site
Sevilla, Spain, 41014
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT03191383     History of Changes
Other Study ID Numbers: 204810
2016-002733-30 ( EudraCT Number )
First Posted: June 19, 2017    Key Record Dates
Last Update Posted: October 15, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through https://www.clinicalstudydatarequest.com/ following the timelines and process described on this site.

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GlaxoSmithKline:
Maternal immunization
Immunogenicity
Vaccines
Safety
Reactogenicity
Respiratory Syncytial Virus

Additional relevant MeSH terms:
Virus Diseases
Respiratory Syncytial Virus Infections
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs